Revelation Biosciences (REVB) AI Stock Analysis

• Market Cap: $3.46M
• Dividend Yield: N/A
• Average Volume (3M): 740.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: N/A
• EPS Growth: 96.26%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 2,623,118
• 10 Day Avg. Volume: 239,834
• 30 Day Avg. Volume: 740,557
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -2.87K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.67
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -14.32
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.50 ▲(66.67% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is primarily held down by weak financial performance (no revenue, widening losses, and worsening cash burn) and a clear bearish technical trend. Corporate events provide some offset via added funding for operations, but valuation support is limited because earnings are negative and no dividend is indicated.

Positive Factors

Modest leverage / balance-sheet flexibility

Low debt relative to equity provides durable financial flexibility for a pre-revenue biotech: it reduces near-term insolvency risk, helps preserve capacity to raise incremental capital on acceptable terms, and supports continued R&D funding without immediate pressure from fixed interest obligations.

Near-term financing extended runway

Fresh gross proceeds materially extend runway for clinical activities and working capital, reducing near-term funding stress. For a development-stage company, this cash lowers the probability of disruptive emergency financing and allows progression of trials and regulatory interactions over the next several months.

Clinical program de-risking / forward path

Completion of Phase 1b with promising signals and a planned FDA meeting represent meaningful program de-risking. Advancing Gemini toward Phase 2/3 in 2026 increases the potential for durable value creation through clinical milestones, partnerships, or licensing over the medium term.

Negative Factors

No revenue / persistent losses

Zero commercial revenue means reliance on capital markets to sustain operations. Persistent net losses limit earnings visibility and long-term sustainability absent successful clinical outcomes or new funding, forcing continued dilution risk and constraining ability to self-fund development.

High and worsening cash burn

Sustained negative operating and free cash flow, with a sharp worsening in the latest period, creates structural runway pressure. Over the next 2-6 months this elevates financing frequency, heightens dilution risk, and can force reprioritization or delays of clinical programs if additional capital is unavailable.

Dilution and financing execution risk

The warrant inducement raised cash but created significant dilution and extended exercisability windows. The withdrawal of an expected investor and advisory fees signal challenging financing dynamics, implying ongoing dilution and potentially less favorable terms for future capital raises.

Revelation Biosciences Business Overview & Revenue Model

Company Description

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

How the Company Makes Money

Revelation Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model may include research and development collaborations, licensing agreements, and potential future product sales. Key revenue streams likely involve partnerships with larger pharmaceutical companies for joint development or commercialization efforts, as well as securing funding through grants or investments to support ongoing research. Currently, as a clinical-stage company, significant earnings may not be realized until products receive regulatory approval and reach the market.

Revelation Biosciences Financial Statement Overview

Summary

Financial statements reflect a pre-revenue biotech with persistent losses and significant ongoing cash burn. The latest annual period shows a sharp deterioration in losses and cash outflows, raising funding/sustainability risk, despite modest leverage.

Income Statement

The company reports no revenue across all provided annual periods, which is common in early-stage biotech but materially limits earnings quality and visibility. Losses are persistent and sizable, with net income negative each year; the 2025 annual period shows an extreme step-up in losses versus prior years, indicating a sharp deterioration in profitability and cost discipline. With zero revenue, margins are not informative, and the overall earnings trajectory is unfavorable.

Balance Sheet

Leverage appears modest in the latest annual period (debt is low relative to equity), which is a balance-sheet positive. However, returns on equity are consistently negative, reflecting ongoing losses and weak capital efficiency. There is also a major year-over-year discontinuity in reported equity and assets in 2025 versus 2024, which increases uncertainty around comparability and underlying financial stability.

Cash Flow

Cash burn is significant and ongoing: operating cash flow and free cash flow are negative in every year provided, and the latest annual period shows a very large deterioration in absolute cash outflows. Free cash flow closely tracks net losses (little evidence of cash generation), and the business does not demonstrate a path to self-funding operations based on these statements.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-14.84B	-7.95M	-8.63M	-10.84M	-11.93M
Net Income	-14.87B	-15.04M	-120.25K	-10.83M	-11.99M
Balance Sheet
Total Assets	11.58B	6.62M	12.21M	5.50M	2.04M
Cash, Cash Equivalents and Short-Term Investments	10.70B	6.50M	11.99M	5.25M	1.27M
Total Debt	746.78M	0.00	0.00	0.00	16.75K
Total Liabilities	2.72B	1.91M	5.56M	4.45M	2.14M
Stockholders Equity	8.86B	4.71M	6.65M	1.05M	-99.47K
Cash Flow
Free Cash Flow	-8.27B	-18.34M	-7.29M	-11.22M	-11.22M
Operating Cash Flow	-8.27B	-18.32M	-7.29M	-11.22M	-11.09M
Investing Cash Flow	0.00	-19.17K	0.00	0.00	-131.96K
Financing Cash Flow	12.47B	12.85M	14.03M	15.20M	8.00M

Revelation Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.51, below the 50-day MA of 2.59, and below the 200-day MA of 7.84, indicating a bearish trend. The MACD of -0.37 indicates Negative momentum. The RSI at 24.89 is Positive, neither overbought nor oversold. The STOCH value of 24.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.

Revelation Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$3.40M	-0.06	-203.36%	―	―	90.53%
REVB	42 Neutral	$3.46M	-0.02	-118.88%	―	―	96.26%
AZTR	41 Neutral	$1.88M	-0.03	-215.04%	―	-100.00%	93.82%
GTBP	40 Underperform	$12.74M	-0.14	-356.99%	―	―	54.62%

Revelation Biosciences Corporate Events

Revelation Biosciences Raises Capital via Warrant Inducement

On January 23, 2026, Revelation Biosciences entered into inducement agreements with two holders of its existing Class I common stock warrants, leading to the immediate cash exercise of 8,544,999 pre-split (2,136,251 post-split) warrants at an effective post-split price of $3.44 per share, generating approximately $7.3 million in gross proceeds to support its clinical development plans, working capital and general corporate needs. In return, the company issued 17,089,998 pre-split (4,272,500 post-split) new Class J common stock warrants in a private placement exempt from registration, with the new warrants becoming exercisable for five years following stockholder approval, while Revelation agreed to file a resale registration statement for the underlying shares and pay Roth Capital Partners an 8% advisory fee; the company also clarified that an initially expected third investor ultimately withdrew, reducing the originally anticipated size of the transaction.

The most recent analyst rating on (REVB) stock is a Hold with a $0.51 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.

Revelation Biosciences Extends Stock Warrants Expiration

On December 3, 2025, Revelation Biosciences held a Special Meeting where stockholders approved the issuance of shares related to Class I Common Stock Warrants, extending their expiration to December 3, 2030. The company also provided a corporate update, highlighting the completion of a Phase 1b clinical study for Gemini in CKD patients, showcasing promising results in inflammation treatment. As they prepare for a meeting with the FDA, Revelation Biosciences plans to advance Gemini’s development for acute kidney injury treatment, aiming to start a Phase 2 or Phase 3 clinical study in 2026.

The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.